Do analysts prefer EDSA or APRE?

Aprea Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 563.51%. Given Aprea Therapeutics' higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Edesa Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is EDSA or APRE more profitable?

Aprea Therapeutics' return on equity of -44.69% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% Aprea Therapeutics N/A -44.69% -39.12%

Does the media refer more to EDSA or APRE?

In the previous week, Edesa Biotech had 5 more articles in the media than Aprea Therapeutics. MarketBeat recorded 7 mentions for Edesa Biotech and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Edesa Biotech's score of 0.78 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is ATOS or APRE more profitable?

Aprea Therapeutics' return on equity of -44.69% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -117.07% -96.08% Aprea Therapeutics N/A -44.69% -39.12%

Does the media refer more to ATOS or APRE?

In the previous week, Atossa Genetics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Atossa Genetics and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Atossa Genetics' score of 1.20 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, APRE or IMMP?

Aprea Therapeutics has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aprea Therapeutics $290K 20.65 -$12.60M -$0.70 N/A Prima BioMed $16.40M 1.58 -$53.82M N/A N/A

Is APRE or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Aprea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aprea Therapeutics N/A -44.69% -39.12% Prima BioMed N/A N/A N/A

Does the media favor APRE or IMMP?

In the previous week, Prima BioMed had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Prima BioMed and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Prima BioMed's score of 0.36 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is APRE or NXTC more profitable?

Aprea Therapeutics' return on equity of -44.69% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Aprea Therapeutics N/A -44.69% -39.12% NextCure N/A -191.33% -125.95%

Does the media favor APRE or NXTC?

In the previous week, NextCure had 5 more articles in the media than Aprea Therapeutics. MarketBeat recorded 7 mentions for NextCure and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat NextCure's score of 0.29 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NextCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer APRE or BKHA?

Aprea Therapeutics presently has a consensus target price of $2.80, suggesting a potential upside of 563.51%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, APRE or BKHA?

Black Hawk Acquisition has lower revenue, but higher earnings than Aprea Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aprea Therapeutics $290K 20.65 -$12.60M -$0.70 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is APRE or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Aprea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aprea Therapeutics N/A -44.69% -39.12% Black Hawk Acquisition N/A N/A N/A

Does the media favor APRE or BKHA?

In the previous week, Black Hawk Acquisition had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Black Hawk Acquisition and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Black Hawk Acquisition's score of 0.61 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Black Hawk Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aprea Therapeutics (APRE) Competitors

$0.42 -0.02 (-4.09%)

As of 03:35 PM Eastern

Compare

APRE vs. EDSA, ATOS, IMMP, NXTC, and BKHA

Should you buy Aprea Therapeutics stock or one of its competitors? Aprea Therapeutics's main competitors and comparable companies include Edesa Biotech (EDSA), Atossa Genetics (ATOS), Prima BioMed (IMMP), NextCure (NXTC), and Black Hawk Acquisition (BKHA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aprea Therapeutics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Aprea Therapeutics' return on equity of -44.69% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Aprea Therapeutics	N/A	-44.69%	-39.12%

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Edesa Biotech has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

In the previous week, Edesa Biotech had 5 more articles in the media than Aprea Therapeutics. MarketBeat recorded 7 mentions for Edesa Biotech and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Edesa Biotech's score of 0.78 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aprea Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 563.51%. Given Aprea Therapeutics' higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Edesa Biotech has higher earnings, but lower revenue than Aprea Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Aprea Therapeutics	$290K	20.65	-$12.60M	-$0.70	N/A

Summary

Aprea Therapeutics beats Edesa Biotech on 10 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Aprea Therapeutics' return on equity of -44.69% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-117.07%	-96.08%
Aprea Therapeutics	N/A	-44.69%	-39.12%

Atossa Genetics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

Aprea Therapeutics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Aprea Therapeutics	$290K	20.65	-$12.60M	-$0.70	N/A

In the previous week, Atossa Genetics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Atossa Genetics and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Atossa Genetics' score of 1.20 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 940.07%. Aprea Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 563.51%. Given Atossa Genetics' higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Aprea Therapeutics beats Atossa Genetics on 11 of the 13 factors compared between the two stocks.

How does Aprea Therapeutics compare to Prima BioMed?

Aprea Therapeutics (NASDAQ:APRE) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Aprea Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 563.51%. Prima BioMed has a consensus target price of $110.00, suggesting a potential upside of 3,038.37%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Aprea Therapeutics has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	20.65	-$12.60M	-$0.70	N/A
Prima BioMed	$16.40M	1.58	-$53.82M	N/A	N/A

In the previous week, Prima BioMed had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Prima BioMed and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Prima BioMed's score of 0.36 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aprea Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market.

Prima BioMed's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	N/A	-44.69%	-39.12%
Prima BioMed	N/A	N/A	N/A

Summary

Aprea Therapeutics and Prima BioMed tied by winning 7 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to NextCure?

Aprea Therapeutics (NASDAQ:APRE) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Aprea Therapeutics' return on equity of -44.69% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	N/A	-44.69%	-39.12%
NextCure	N/A	-191.33%	-125.95%

Aprea Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, NextCure has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aprea Therapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	20.65	-$12.60M	-$0.70	N/A
NextCure	N/A	N/A	-$55.84M	-$6.77	N/A

In the previous week, NextCure had 5 more articles in the media than Aprea Therapeutics. MarketBeat recorded 7 mentions for NextCure and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat NextCure's score of 0.29 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NextCure	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aprea Therapeutics presently has a consensus target price of $2.80, indicating a potential upside of 563.51%. NextCure has a consensus target price of $20.00, indicating a potential upside of 216.36%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aprea Therapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
NextCure	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aprea Therapeutics beats NextCure on 11 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Black Hawk Acquisition?

Aprea Therapeutics (NASDAQ:APRE) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Aprea Therapeutics presently has a consensus target price of $2.80, suggesting a potential upside of 563.51%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aprea Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Black Hawk Acquisition's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	N/A	-44.69%	-39.12%
Black Hawk Acquisition	N/A	N/A	N/A

Black Hawk Acquisition has lower revenue, but higher earnings than Aprea Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	20.65	-$12.60M	-$0.70	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Black Hawk Acquisition had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Black Hawk Acquisition and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.82 beat Black Hawk Acquisition's score of 0.61 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Black Hawk Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

34.2% of Aprea Therapeutics shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aprea Therapeutics beats Black Hawk Acquisition on 8 of the 11 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.99M	$4.11B	$7.88B	$12.07B
Dividend Yield	N/A	3.62%	2.46%	4.50%
P/E Ratio	-0.60	24.61	34.60	30.46
Price / Sales	20.65	16.97	8.93	5.89
Price / Cash	N/A	26.89	22.23	22.80
Price / Book	0.18	4.15	4.42	3.79
Net Income	-$12.60M	-$22.78M	$3.51B	$390.67M
7 Day Performance	-18.47%	-2.43%	-1.28%	-0.30%
1 Month Performance	-29.67%	-5.42%	-3.70%	-6.64%
1 Year Performance	-64.54%	0.07%	1.15%	-5.79%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	3.6554 of 5 stars	$0.42 -4.1%	$2.80 +563.5%	-65.1%	$5.99M	$290K	N/A	8	Positive News Gap Up
EDSA Edesa Biotech	1.4952 of 5 stars	$2.28 -6.6%	N/A	+16.2%	$23.52M	N/A	N/A	17	Gap Down
ATOS Atossa Genetics	3.2566 of 5 stars	$2.33 +1.3%	$20.33 +772.7%	-84.1%	$22.95M	N/A	N/A	14	Positive News Earnings Report
IMMP Prima BioMed	2.631 of 5 stars	$3.00 -2.4%	$110.00 +3,572.8%	-89.8%	$22.63M	$16.40M	N/A	53
NXTC NextCure	3.2047 of 5 stars	$5.91 +3.7%	$19.00 +221.5%	-32.9%	$20.57M	N/A	N/A	40	News Coverage Earnings Report Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. EDSA, ATOS, IMMP, NXTC, and BKHA

How does Aprea Therapeutics compare to Edesa Biotech?

Summary

How does Aprea Therapeutics compare to Atossa Genetics?

Summary

How does Aprea Therapeutics compare to Prima BioMed?

Summary

How does Aprea Therapeutics compare to NextCure?

Summary

How does Aprea Therapeutics compare to Black Hawk Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. EDSA, ATOS, IMMP, NXTC, and BKHA

How does Aprea Therapeutics compare to Edesa Biotech?

Is EDSA or APRE more profitable?

Do insiders and institutionals hold more shares of EDSA or APRE?

Which has more risk & volatility, EDSA or APRE?

Does the media refer more to EDSA or APRE?

Do analysts prefer EDSA or APRE?

Which has better earnings and valuation, EDSA or APRE?

Summary

How does Aprea Therapeutics compare to Atossa Genetics?

Is ATOS or APRE more profitable?

Which has more risk and volatility, ATOS or APRE?

Which has stronger valuation and earnings, ATOS or APRE?

Does the media refer more to ATOS or APRE?

Do institutionals & insiders hold more shares of ATOS or APRE?

Do analysts recommend ATOS or APRE?

Summary

How does Aprea Therapeutics compare to Prima BioMed?

Do analysts prefer APRE or IMMP?

Which has preferable earnings and valuation, APRE or IMMP?

Does the media favor APRE or IMMP?

Do institutionals & insiders have more ownership in APRE or IMMP?

Which has more volatility and risk, APRE or IMMP?

Is APRE or IMMP more profitable?

Summary

How does Aprea Therapeutics compare to NextCure?

Is APRE or NXTC more profitable?

Which has more volatility & risk, APRE or NXTC?

Do institutionals and insiders believe in APRE or NXTC?

Which has better earnings and valuation, APRE or NXTC?

Does the media favor APRE or NXTC?

Do analysts rate APRE or NXTC?

Summary

How does Aprea Therapeutics compare to Black Hawk Acquisition?

Do analysts prefer APRE or BKHA?

Which has more volatility & risk, APRE or BKHA?

Is APRE or BKHA more profitable?

Which has better earnings & valuation, APRE or BKHA?

Does the media favor APRE or BKHA?

Do insiders & institutionals believe in APRE or BKHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools